Three anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) (i.e., pembrolizumab, nivolumab, and atezolizumab) have been approved for the treatment of metastatic NSCLC based on several large and pivotal clinical trials [13,14,15]. Here, PDCD1 is linked to non-small cell lung carcinoma.